1. Introduction {#sec1}
===============

The complexity and multitude of functions the brain controls require equally intricate and robust barriers to this organ. At present, there are three agreed upon main regulators to access the brain: The Blood-Brain Barrier (BBB), the blood--CSF barrier, and the arachnoid barrier. These barriers strictly regulate homeostasis within the brain. This selectivity protects the brain from many pathogens, harmful compounds and other foreign material. However, problems arise when cells within the brain become abnormal, or when foreign material crosses the barrier and invades the brain tissue. The BBB that once protected healthy brain tissue, in effect becomes the greatest obstacle to the delivery of therapeutics. The BBB by area is one of the largest of the aforementioned brain barriers, with an area of approximately 20 m^2^ with a total capillary length of over 600 km \[[@r1]\]. In terms of brain density this vascular barrier is extremely dense, with a neuron never being more than a median distance of 50 micron away from a brain capillary \[[@r2]\]. The BBB in comparison to the blood-CSF barrier, is less invasive to target and has a greater blood flow rate making it an attractive option for targeting therapeutics to the brain \[[@r3]\]. The arachnoid barrier, like the BBB has a number of efflux transporters that reduce the retention time of molecules able to pass through the plasma membrane into the cytosol before being kicked out again. However, the arachnoid barrier compared in terms of surface area to the BBB is vastly smaller \[[@r4], [@r5]\]. The olfactory bulb has recently become the focus of renewed interest in reaching the brain \[[@r6]\].This barrier to the brain is more permissible but has a vastly reduced surface area. Additionally, the presence of mucus entraps many compounds before they can even make it to the olfactory bulb and thus into the brain \[[@r7]\]. The BBB is composed of three cell types, endothelial, astrocytes and pericytes (Fig. **[1](#F1){ref-type="fig"}**). Together they are described as a neurovascular unit, that act *in situ* to maintain tight junctions, and efficient efflux mechanisms \[[@r5], [@r8]\]. These tight junctions produce high Transendothelial Electrical Resistance (TEER) values as high as 2000 Ω·cm \[[@r2], [@r9]\]. This in turn highlights the polarity between the luminal and abluminal side of the barrier. Requiring the barrier to have highly developed uptake mechanisms. Transport can be split into two areas, uptake (influx) and efflux. Efflux transporters of the ATP-binding cassette (ABC) family (P-glycoproteins) and Solute Carrier Family (SLC) play essential roles in the BBB permeability of small molecules, both endogenous compounds and xenobiotics \[[@r10], [@r11]\]. Uptake can be further split into 3 mechanisms, receptor-mediated endocytosis, adsorptive uptake and passive diffusion (Fig. **[2](#F2){ref-type="fig"}**) \[[@r3]\]. Receptor-mediated uptake offers the most comprehensive system studied at present. Although many authors in the field still believe that much more remains to be discovered. Several receptor systems have been reported that actively mediate transcytosis of molecules from the basal to the apical side, for example insulin, LRP-1, LDL and transferrin to name but a few \[[@r12]-[@r19]\]. Targeting these receptors has several advantages; being selectable, with promising indications of regiospecificity within the brain \[[@r20]\]. However, receptor-mediated targets are a saturable route, with compounds quickly overloading the receptors targeted. Other mechanisms such as passive and adsorptive transport are non-saturable, but lack specificity. Highly lipophilic compounds are predominately transported via passive diffusion \[[@r21], [@r22]\]. Peptides with a highly cationic electrostatic nature create deformations, which develop into pits across the cell membrane. As the peptide enters these pit formations, their presence continues to extend and deform the membrane. Finally the peptide is fully encapsulated within a newly formed vesicle, within the cytosol \[[@r23]-[@r25]\]. This mechanism is non-saturable and non-specific.

Diseases afflicting the brain, such as metastatic brain cancer have extremely poor prognosis and are the most common form of neurologic complications. At present reports conclude that the incidence is between 9%-17% for metastatic brain cancer \[[@r26]\]. Nevertheless, it is generally accepted that the exact incidence will be much higher. Current treatments fail to be effective against this aggressive form of cancer. They are either prevented from passing into the brain, rapidly effluxed, or metabolised by the body before ever reaching their target. Those treatments that can cross require such large doses to be effective that they induce toxicity elsewhere in the body. From this perspective, a more specific, targeted, and less toxic approach is needed. A promising tool in development has been the discovery of peptides that can cross the BBB by transcytosis. These peptides can target the brain specifically, circumvent rapid efflux mechanisms from the brain and are designed to prevent degradation \[[@r27]\].

Combining peptide shuttles with nanoparticles conjugated with a therapeutic drug have the potential to target the brain with minimal disruption and toxicity. At present most clinical treatments are highly invasive, vastly disruptive and create a plethora of unwanted side effects \[[@r28]-[@r31]\].

Within the field of nanomedicine, the diversity in nomenclature that exists has grown rapidly over the last few years. In many regards, much of the terms used had to be created to define the uniqueness of the properties being observed. However, this explosion in nomenclature has come at a price. Each new term initially has very limited penetration within the nanomedicine community's lexicon. Often leading to competing and sometimes contradictory definitions, it is within this context that we must clearly define what terms we are describing, until a globally accepted definition has been agreed upon. For example, describing the property of a peptide to cross the BBB has been described as a BBB-shuttle, a BBB carrier and a molecular Trojan horse. The last example was first coined by William M Pardridge *et al.* (1986); however, these molecular Trojan horses were made from modified large proteins and antibodies. The BBB-shuttle concept relating to peptides to enable passive transport across the BBB was proposed by Teixidó *et al.* (2007) and later expanded by Malakoutikhah *et al.* (2008) to include receptor-mediated transport \[[@r32], [@r33]\]. They defined BBB-shuttles in terms of being solely peptidic in nature, excluding large proteins and antibodies from the definition, to differentiate between the advantages peptides would have over larger molecules defined as molecular Trojan horses. Recently a third definition for BBB-shuttles has arisen by Webster *et al.* (2015) defining BBB-shuttles as the receptors, engineered ligands to these receptors as 'BBB carriers', and drugs attached to these 'carriers' being classed as molecular Trojan horses \[[@r34]-[@r37]\]. Other groups have reported and defined brain shuttles as modified antibodies able to cross the BBB via transcytosis \[[@r18], [@r38]\]. The examples mentioned above are just a few cases illustrating the complexity of the nomenclature. However, terms are not always mutually exclusive, for example carriers have been defined as objects with the ability to directly transport cargo such as siRNA, drugs, and fluorophore across the BBB \[[@r39]-[@r42]\]. With this definition of a carrier, a BBB-shuttle able to cross into the parenchyma of the brain with an attached cargo could equally be described as both a BBB-shuttle and a BBB-carrier.

For the purposes of this review, we will consolidate these competing terms and clarify our definitions on the following. A BBB-shuttle will be defined within the context of this review as a peptide that can cross the BBB by either passive or active transport mechanisms and crucially, can transport other components attached to this molecule. The components attached to the BBB-shuttle will also be deemed as the cargo. Finally, a unifying term is required to talk about the shuttle with the cargo, to describe its size. For this we propose the terms constructs for entities larger than 100 nm, and nano-constructs, for when the overall size is below 100 nm including the hydrodynamic diameter.

2. Blood-brain barrier shuttles (BBB-shuttles) {#sec2}
==============================================

In 1986, William M Pardridge began to pursue the idea of proteins targeting cell receptors to cross the BBB; eventually coining the molecular Trojan horse concept. These early modified proteins and antibodies were large, had high affinity to receptors, but poor release. Since then a new class of small peptides targeting receptors has arisen. When the first CPP was described in 1998, a lot of excitement over the subsequent years was generated by the prospect that these CPPs could cross any cellular barrier \[[@r43]-[@r46]\]. However, this excitement gave way to the reality that not all CPPs could cross and crucially, remain in the parenchyma. This lead to more in-depth studies on the role of efflux, influx, rate of transport and the extent to which the CPP could penetrate. Stalmans *et al.* (2015) investigated the balance between these CPP properties \[[@r47]\]. Selecting five different CPPs they evaluated to what extent the CPP can cross the BBB (influx) and how quickly is the CPP removed from the BBB (efflux). They selected five structurally distinct CPPs; pVEC, SynB3, Tat 47-57, transportan 10 (TP10) and TP10-2 (Fig. **[3](#F3){ref-type="fig"}**).

Their findings concluded SynB3, Tat 47-57 and pVEC displayed initial high brain influx rates, by a non-saturable mechanism. TP10 and TP10-2 produced low influx and higher efflux rates. Excluding pVEC, the remaining CPPs were significantly effluxed from the neurovascular unit. This study highlights the importance of peptide choice and design. This study contributed to the difference between CPPs and BBB-shuttles. Whilst CPPs by their very nature can be internalised, only a small subset are capable of transcytosis. It's this ability to transcytosis that differentiates CPPs from BBB-shuttles (Fig. **[4](#F4){ref-type="fig"}**).

2.1. Receptor-Mediated {#sec2.1}
----------------------

At present a number of peptides exist that target only a small class of receptors. The low density lipid receptor (LDLR) is a cell surface receptor responsible for cholesterol and apoprotein uptake, ubiquitous in epithelial cells and endothelial brain tissue. Several groups have sought to target this receptor using repeats of lysine, arginine and leucine (ApoE) (Table **[1](#T1){ref-type="table"}**) identified from natural proteins \[[@r39], [@r48], [@r49]\]. Other receptors include leptin, receptor-associated protein (RAP), insulin, scavenger receptor type B1 (SCARB1) and Fc like growth factor receptor (FCGRT) \[[@r31]\]. The transferrin receptor (TfR) mediates iron uptake and metabolism into the brain parenchyma *via* the BBB. At present, this receptor is one of the most targeted for therapeutics (Table **[1](#T1){ref-type="table"}**). TfR is essential for iron uptake in many cell types, with its highest expression observed in the bone marrow \[[@r50]\]. As a candidate target the transferrin receptor has shown some remarkable results as a mode to access the brain parenchyma. However, modulation of this receptor may have off-target effects. TfR modulation has been linked to mitochondrial respiration, the generation of reactive oxygen species, as well as the induction and maintenance of oncogenesis \[[@r51]\]. Despite this current array of receptors and peptides, much more research must be done

to find novel routes into the brain. A paper by Holton *et al.* (2013) put forward the idea to "mine" viral sequences to find promising new CPP's and antibiotics \[[@r52]\]. This "bio-prospecting" opens up a vast new avenue to explore novel receptors and ligands for the BBB, as the full extent of its complexity has not yet been elucidated.

2.2. Peptide Design: Cyclic or Linear {#sec2.2}
-------------------------------------

Many of the peptides, which have been found to have shuttling capacity, have been synthesized to be linear, *e.g*. ApoE, AngioPep2, THR, RVG, *etc*. (Table **[1](#T1){ref-type="table"}**). However, linear peptides can be enzymatically degraded much quicker than cyclized peptides in plasma \[[@r5], [@r53]-[@r57]\]. Oller-Salvia *et al.* (2016) showed the stability of a miniaturized cyclic version of the Apamin protein derived from bee venom \[[@r54]\] (Table **[1](#T1){ref-type="table"}**). Other groups have shown similar trends with peptide cyclisation improving stability such as Peptide-22 \[[@r58]\] and CRT \[[@r59]\] (Table **[1](#T1){ref-type="table"}**). However, shuttling capacity does not seem to be dependent on cyclisation, rather the benefit of cyclisation appears to be the increased stability of the peptide \[[@r60]\].

### 2.2.1. Chirality {#sec2.2.1}

Chirality can be defined as the property of disymmetry, *i.e*. being non-superimposable to their mirror image. Peptide and proteins are chiral compounds. This chirality derives from the chirality of the amino acids that can exist in an L- or D- format. However, in nature, only L- amino acids are used. This offers some interesting possibilities, as D- amino acids have the same properties as L- amino acids, with some notable exceptions. When a peptide is made with one or more D- amino acids, protease enzymes within our body are no longer able to recognise and cleave these D- structures \[[@r61], [@r62]\]. This property means that, we can design peptides with similar functions to the natural L- peptide but with vastly increased resistance to proteases. However, there is a caveat with this approach to produce D- peptides. The sequence must be reversed to mimic the function of the original L- form; this method is called the retro-enantio approach \[[@r63], [@r64]\]. Several studies have shown increased BBB permeation using peptide resistant D-versions of BBB-shuttles \[[@r47]-[@r51]\]. Another approach is to pinpoint the exact areas of a peptide sequence, which is prone to degradation and to substitute this amino acid with the D- version.

### 2.2.2. BBB-Shuttle Binding and Release {#sec2.2.2}

BBB-shuttles must be able to bind to their receptors to allow trafficking. However, it must also be noted that the affinity of the peptide to the receptors must also be considered. It would not be desirable to have a peptide that can bind with such a high affinity to a desired receptor that it could no longer be released. This has been shown by studies with high affinity antibodies to target the BBB. They found by lowering the binding affinity, the antibodies were able to escape lysosomal degradation and enter the parenchyma \[[@r65], [@r66]\].

Clark *et al.* (2015) designed an acid cleavable linker between a high affinity transferrin receptor ligand and a gold nanoparticle. This cleavable linker resulted in a significant increase of gold nanoparticles being found within the mice parenchyma. They concluded that targeting with high affinity comes at a cost. The high binding strength between ligand and receptor can prevent further penetration into the tissue, in turn leading to degradation of the construct by lysosomal sorting \[[@r67]\].

3. BRAIN DELIVERY OF nanoparticles WITH BBB-shuttles {#sec3}
====================================================

BBB-shuttles can cross the parenchyma of the brain; however, directly attaching therapeutics onto the BBB-shuttle in a 1:1 ratio can drastically limit the potential potency of the drug and the shuttle combination. Using nanoparticles decorated with BBB-shuttles and containing various copies of the therapeutic cargos, we can increase the potency of both. An exhaustive analysis of the current examples of BBB-shuttle modified NPs is depicted in Table **[1](#T1){ref-type="table"}**, where the main characteristics of the NP system and evaluation of the BBB-shuttle properties have been described. The majority of studies discussed within this review compare modified and unmodified nano- submicroparticles showing a clear benefit when decorated with BBB-Shuttles. However, the impact of size has not been studied systematically in relation to BBB-shuttles and their corresponding uptake/transport efficiencies.

3.1. Gold {#sec3.1}
---------

Gold Nanoparticles (AuNPs) have been extensively used for drug delivery for *in vitro* and *in vivo* studies \[[@r22], [@r71], [@r72], [@r99], [@r102]-[@r113]\]. This is due to their many desirable qualities. It can be tailored to many different sizes very easily, with multifunctional moieties using thiol bonds \[[@r107]\]. PEGylated AuNPs are highly stable *in vivo*, and have been shown to be very biocompatible \[[@r107]\]. As a delivery system, AuNPs have been studied extensively with many studies discussing the role of stabilization and release kinetics \[[@r114]\]. In the field of BBB-shuttles, AuNPs have been used in several studies \[[@r22], [@r27], [@r42], [@r72], [@r85], [@r99], [@r115]-[@r121], [@r128]\] (Table **[1](#T1){ref-type="table"}**). One of the first studies to combine gold nanoparticles with a specifically designed amphiphilic peptide to improve uptake into the brain was performed by Guerrero *et al.* (2010) \[[@r22]\] (Table **[1](#T1){ref-type="table"}**). Comparing AuNPs conjugated to the peptide LPFFD with unlabelled AuNPs, the authors demonstrated that the peptide conjugates improved the delivery to the brain by four-fold. However, AuNPs are still beset with a number of issues, there mechanism of clearance from the brain is still unknown and the long term effects of AuNPs on the brain have yet to be elucidated \[[@r122], [@r123]\].

3.2. Iron-Based Nanoparticles {#sec3.2}
-----------------------------

Superparamagnetic iron oxide nanoparticles (SPIONs) require more complex chemistry to provide stable nanoparticles, but do offer some excellent advantages over gold nanoparticles. Their magnetic properties can be used to target to specific region under a magnetic field. Using T1 and T2 relaxivity properties in MRI, it is possible to view highly defined regions in real time of nanoparticle uptake. Many reports have shown the biocompatibility and low toxicity of SPIONS, over short-term experiments. However, it has not been fully elucidated as to the long-term impact of SPIONs in the body under repeated doses and how the NPs are cleared from tissue. A study by Engberink *et al.* (2010) put forward a possible clearance mechanism of iron oxide nanoparticles by cervical lymph nodes after passing the BBB into the brain \[[@r124]\].

Some reports have shown that high SPION concentrations increase the Reactive Oxygen Species (ROS) that can be found in tissues with SPIONs inside, inducing possible mutagenic effects \[[@r125]\]. An increase in Alzheimer's like aggregates and neurodegeneration has also been associated with SPIONS \[[@r126]\]. Despite this, promising results have shown that SPIONs, can be functionalised with shuttles and cargo and are able to effectively and efficiently cross the BBB \[[@r94], [@r108]\] (Table **[1](#T1){ref-type="table"}**).

3.3. Polymer-Based Nanoparticles {#sec3.3}
--------------------------------

Polymer-based nanoparticles offer the most US Food and Drug Administration (FDA) and European Medicines Agency (EMA) friendly route to the clinic. The polymers themselves can be broken down into harmless by-products, circumventing some of the clearance issues associated with inorganic nanoparticles. Poly(ethylene glycol) (PEG) poly(glycolic acid) (PGA), poly(lactic acid) (PLA) and Poly(lactic-co-glycolic acid) (PLGA), have been approved by the FDA and EMA for certain medical applications. PLGA has been the most studied and successful polymer for drug delivery. It is highly biocompatible and its by-products can be used within the bodies Krebs cycle \[[@r127], [@r128]\]. The problems arising from polymer based nanoparticles, is size, drug loading, stability and leakage \[[@r129]\]. It is much more difficult to produce nanoparticles within a small distribution; with many formulations existing over a large range. It has been shown that, polymer based nanoparticles can leak out their cargo or spontaneously burst \[[@r127], [@r129], [@r130]\]. This has major implications for their long-term stability and use in the clinic. Some polymers, such as PEI, have been used to electrostatically maintain cargos within PLGA polymer-based nanoparticles \[[@r117], [@r131]-[@r133]\]. PEI can stabilize encapsulated cargo, and allow for higher loading. These advantageous properties are offset by PEI's cytotoxicity. Furthermore at present, PEI is not FDA or EMA approved. In 2012, the EMA granted an "orphan designation" to allow clinical trials of a construct combining DOX-PEI-siRNA against claudin 5 to treat glioma. In 2017 however, the product was withdrawn, with no clinical trials taking place. Others have combined PLGA with PEG to stabilize the nanoparticles and increase the clearance time *in vivo* \[[@r76], [@r90], [@r97], [@r134]\] (Table **[1](#T1){ref-type="table"}**).

3.4. Liposomal Nanoparticles {#sec3.4}
----------------------------

Liposomal nanoparticles have been trialled for many years and were among the first theranostics developed. Some formulations have even progressed into the clinic. In 2013, a GSH labelled liposome containing doxorubicin reached phase II clinical trials (ClinicaTrials.gov identifier: NCT01818713). Liposomes have some excellent physicochemical characteristics, being able to incorporate a vast array of lipophilic, hydrophilic or hydrophobic moieties \[[@r135]\]. Several groups have combined liposomal technology with BBB-shuttles to target the brain and release various therapeutics \[[@r136]-[@r139]\]. Recently, Chen *et al* (2017) proposed a dual BBB-shuttle labelled liposome approach to cross the BBB. They found that the cyclic RGD peptide with the BBB-shuttle peptide-22 could significantly cross the BBB and localize to glioma cells \[[@r100]\] (Table **[1](#T1){ref-type="table"}**). However, not all liposomes are created equally and the starting material considered is highly important for drug release and stability. A recent report by Hu *et al.* (2017) showed that egg-yolk phosphatidylcholine (EYPC) shuttled significantly higher levels of the drug MTX into the brain via the BBB using GSH. In comparison, a hydrogenated soy phosphatidylcholine (HSPC) displayed poorer permeation into the parenchyma. Confirming once again the importance of the starting material \[[@r140]\].

Despite promising advances into the clinic, liposomes still have some issues with targeting. As highly cationic liposomes tend to accumulate in peripheral organs \[[@r135], [@r141], [@r142]\]. Targeting could be vastly improved in clinical studies by combining the encapsulation efficiency of liposomes and the targeting of peptide based shuttles across the BBB. *In vivo* studies by Ying *et al.* (2016) and Song *et al.* (2016) combined BBB-shuttles and liposomes to increase transport. Both studies reported increased targeting of liposomes into the brain \[[@r143], [@r144]\].

4. Nano-, submicro-, microparticles {#sec4}
===================================

As mentioned previously, the field of particle science is diverse. With thousands of articles being published year after year, the field has become highly divergent in vocabulary; accelerating a growth in confusion and contradictions. In 2008 and later in 2015, the International Standards Organization (ISO) aimed to bring an ordered and unified set of definitions to describe nanoscale materials and indeed to even define the "nanoscale". The ISO issued guidelines defining a nanoparticle as an object with 3 dimensions below 100 nm (Fig. **[5](#F5){ref-type="fig"}**) \[[@r145]\]. They deemed under 100 nm to be the most appropriate cut off for nanoparticles, as it is within this range that most of the special properties characterized by being "nano" are exhibited. However, the field has been very relaxed to stick within the confines of this definition, with many papers reporting "nanoparticles" with sizes above 100 nm for years. Building upon the ISO "nano" definition, any particle therefore with any of the 3 dimensions greater than 100 nm and below 1000 nm should therefore be classed as a submicroparticle (SMP). It is within these confines that we can truly grasp the complexity and variability within the field.

4.1. Nanoconstructs and Submicroconstructs {#sec4.1}
------------------------------------------

With this in mind, it is still difficult in global terms to talk definitively about engineered nanoparticles. For example when discussing the size of a 50 nm iron oxide nanoparticle, does this size refer to the core or the hydrodynamic radius? Are we discussing an unmodified or modified nanoparticle? From the current definitions, it would not be incorrect to talk about a 50 nm nanoparticle core as a nanoparticle, yet in global terms the functionalization of the nanoparticle with additional moieties (such as PEG) could produce a particle with a hydrodynamic diameter larger than 100 nm. In this scenario, the engineered "nanoparticle" exceeds the nanoparticle definition. We propose using the term constructs to encompass the global size of engineered particles. In the case of our previous example, the iron oxide functionalised with PEG should be considered as a submicroconstruct (SMC), as it no longer falls within the nanoscale limit as defined by the ISO. Extension engineered particles less than 100 nm should be referred to as nanoconstructs (NC). We believe the practicalities of using this form of terminology adds clarity of expression and more precision to the field.

5. Future works and current limitations {#sec5}
=======================================

At present, the combination of nanoparticles and peptides arriving to the clinic is extremely limited. Of note, is a formulation by the company 2-BBB Medicines. Using liposomes with a GSH peptide and a therapeutic cargo of doxorubicin, they aim to target metastatic cancer within the brain. This formulation has successfully progressed to phase II clinical trials, being the only nanoparticle modified with BBB-shuttles to do so (Integrity database: 698269).

However, the arrival to the clinic of these nanoconstructs does not hide the fact that at present our understanding of the clearance mechanisms of nanoparticles from tissues requires greater levels of research. Additionally, the long-term effects of these nanoconstructs is unknown, and will require many more years of observation and research before their long-term effects can be fully understood. Finally, the toxicity of the nanoconstructs to the environment is another area where our knowledge and research is at best sparse. Nevertheless, the direction of therapeutic research is heading towards the combination of novel nanomaterials with targeting moieties.

Conclusion
==========

The rapid convergence and expansion of both the peptide shuttles field and the nanoparticle field have furthered our basic understanding of disease and offer huge potential to combine transport with therapies. However, this rapid pace has posed many challenges. Firstly terminology, although at first glance a trivial matter, has huge implications on whether a new therapeutic needs to undergo more or less stringent regulatory assessments. Secondly, although hugely promising objects for theranostics applications, nanoconstructs (1-100 nm) must be carefully and stringently assessed for toxicity and stability. Many studies still have to be carried out to fully assess the long-term effects and clearance mechanisms. These hurdles are not insurmountable but will slow down translation from the bench to the bedside. Thirdly, peptides offer the most exciting avenue to target towards cells of interest and cross biological barriers. However, they too have to be assessed for toxicity, and potential off-target effects. For example, peptides that are able to cross the BBB may also potentiate other as of yet undiscovered factors, producing off-target effects. On the contrary, combining the fantastic targeting properties of peptides and the diverse applications of nanoparticles, the next decade offers fantastic opportunities to target, treat and terminate the worst ailments of humanity.
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![Detailing the different barriers to the brain. **A**) The Arachnoid barrier, showing efflux pump transporters and endothelial cells. **B**) The blood-brain barrier is composed of the neurovascular unit (endothelial, pericytes and astrocytes cells with a basement membrane lining). **C**) The CSF barrier is composed of epithelial and endothelial cells.](CPD-24-1366_F1){#F1}

![Diagram describing various models of uptake of material for BBB endothelial cells. Detailing clathrin-, caveolin- mediated endocytosis and clathrin/caveolin independent mechanisms. The difference between CPPs and BBB-Shuttles is shown with CPPs being exocytosed to the lumen whilst BBB-Shuttles are transcytosed.](CPD-24-1366_F2){#F2}

![Comparing the rate of influx from the blood to the brain and efflux from the brain to the blood of several CPPs \[[@r47]\]. Image reproduced with permission.](CPD-24-1366_F3){#F3}

![Comparing the properties of CPPs and BBB-Shuttles.](CPD-24-1366_F4){#F4}

![ISO definition of nanoparticles, nanowires and nanoplates.](CPD-24-1366_F5){#F5}

###### 

Features of selected BBB-shuttle modified NPs.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **BBB- Shuttle**      **Target**                      **Sequence**                                            **NP Composition**                              **Therapeutic Moiety**          **Size (nm)^a^**                   ***In vitro* Evaluation^b^**   ***In vivo* Evaluation^c^**   **Ref.**                                          
  --------------------- ------------------------------- ------------------------------------------------------- ----------------------------------------------- ------------------------------- ---------------------------------- ------------------------------ ----------------------------- --------------------- --------------------------- -------------
  Ang-2                 LDR 1                           TFFYGGSRGKRNNFKTEEY                                     PLGA/chitosan                                   siRNA (EGFR)\                   190                                •                              •                             •                     •                           \[[@r68]\]
                                                                                                                                                                Doxorubicin                                                                                                                                                                       

  PEG-Liposomes         Perfluoro-\                     144 (LP)\                                               •                                               \-                              •                                  \-                             \[[@r69]\]                                                                      
                        propane gas                     525 (BL)                                                                                                                                                                                                                                                                                  

  AuNP-PEG              Doxorubicin                     39.9                                                                                                    •                               •                                  •                              \[[@r70]\]                                                                      

  AuNRs-PEG             D1 peptide^e^                   11x97                                                   •                                               •                               •                                  •^f^                           \[[@r71],[@r72]\]                                                               

  Yeetkfnnrkgrsggyfft   PEG-Liposomes                   Coumarin and DiR                                        12-16                                           •                               •                                  •                              •                             \[[@r73]\]                                        

  ApoE (141-150)        LDLR                            (LRKLRKRLLR)\                                           Nanoliposomes                                   Phosphatidic\                   136\                               •                              •                             \-                    \-                          \[[@r74]\]
                                                        (LRKLRKRLLR)~2~                                                                                         acid or\                        146                                                                                                                                               
                                                                                                                                                                cardiolipin                                                                                                                                                                       

  LRKLRKRLLR\           PLGA                            \-                                                      220                                             •                               •                                  •                              \-                            \[[@r75]\]                                        
  Or L-PGDS                                                                                                                                                                                                                                                                                                                                       

  B6                    hTrR                            CGHKAKGPRK                                              PEG-PLA                                         Neuroprotective\                120                                •                              •                             •                     •^g^                        \[[@r76]\]
                                                                                                                                                                Peptide (NAP)                                                                                                                                                                     

  SeNP                  Sialic acid ^e^                 95                                                      •                                               •                               \-                                 \-                             \[[@r77]\]                                                                      

  Cyclic-RGD            Integrin R                      &RGDfK&^h^                                              PEG-PolyQ                                       DACHPt                          28-31                              \-                             •                             \-                    •                           \[[@r78]\]

  CDX                   nAchR                           FKESWREARGTRIERG                                        mPEG--PLA micelles                              DiR/PTX                         39                                 •                              \-                            •                     •                           \[[@r79]\]

  ^D^CDX                nAchR                           GreirtGraerwsekf-OH                                     HSPC/cholesterol/mPEG2000-DSPE                  DiR/Dox                         50-200 nm                          •                              \-                            •                     •                           \[[@r80]\]

  Enk\                  Opioid receptor                 YGGFL\                                                  AuNP                                            NOTA-Gd                         2-3 ^i^                            \-                             \-                            •                     \-                          \[[@r81]\]
  Gly-copep                                             GGYTGFLS-O-beta-glucoside                                                                                                                                                                                                                                                                 

  g7                    Unknown                         GFtGFLS-(monosaccharide) (derived from opioid family)   PLGA-RG503H                                     \-                              162-212 ^j^                        \-                             \-                            •                     \-                          \[[@r82]\]

  gH625                 Unknown                         Ac-HGLASTLTRWAHYNALIRAFGGG-COOH                         orange fluorescent amine-modified polystyrene   \-                              96                                 •                              •                             \-                    \-                          \[[@r42]\]

  Gluthatione           Mrp/\                           GSH                                                     PEI                                             DNA                             117                                •                              •                             \-                    \-                          \[[@r83]\]
                        Abcc                                                                                                                                                                                                                                                                                                                      

  LPFFD                 RAGE?                           LPFFD                                                   AuNP                                            \-                              13                                 •                              \-                            •                     \-                          \[[@r22]\]

  MiniAp-4              Unknown                         Dap(&)KAPETALD(&)                                       Qdots, AuNP                                     \-                              10-15 (QDs),^j^ 12 nm (AuNP) ^i^   •                              \-                            •                     \-                          \[[@r84]\]

  Penetratin            CPP                             RQIKIWFQNRRMKWKK                                        PEG-AuNanostars                                 Ru                              105                                •                              •                             •                     \-                          \[[@r85]\]

  **BBB- Shuttle**      **Target**                      **Sequence**                                            **NP Composition**                              **Therapeutic Moiety**          **Size (nm)^a^**                   ***In vitro* Evaluation^b^**   ***In vivo* Evaluation^c^**   **Ref.**                                          

                                                                                                                                                                                                                                   **Uptake**                     **Toxicity**                  **Biodistribution**   **Therapeutic Impact^d^**   

  RDP peptide           nAchR                           KSVRTWNEIIPSKGCLR\                                      BSA covered AuNanoclusters                      \-                              10 nm                              •                              •                             •                                                 \[[@r86]\]
                                                        VGGRCHPHVNGGGRRRRRRRRR                                                                                                                                                                                                                                                                    

  RVG29                 nAchR                           YTWMPENPRPGTPCDIFTNSRGKRASNGGGGGGC                      Pluronic and chitosan                           β-galactoside                   142-162 (25^o^C)\                  \-                             \-                            \-                    •                           \[[@r87]\]
                                                                                                                                                                                                52-65 (37^o^C)                                                                                                                                    

  CTX                   MMP-2, Annexin A, Cl-channels   MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR                    PLGA-PLL NP                                     NEP1-40\                        150 nm                             \-                             \-                            •                     •                           \[[@r88]\]
                                                                                                                                                                (IR780)                                                                                                                                                                           

  T7-HAI                TfR                             HAIYPRH                                                 MNP coencapsulated in PLGA                      Paclitaxel and\                 130                                •                              •                             \-                    •                           \[[@r89]\]
                                                                                                                                                                curcumin                                                                                                                                                                          

  HAIYPRH               Micelle PEG-PLGA                Carmustine                                              83                                              •                               •                                  \-                             •                             \[[@r90]\]                                        

  C-HAIYPRH             DGL-PEG                         siRNA\                                                  143                                             •                               \-                                 \-                             •                             \[[@r91]\]                                        
                                                        Dox                                                                                                                                                                                                                                                                                       

  HAIYPRH               PEG-liposome                    ZL006                                                   73-74                                           •                               •                                  \-                             • ^k^                         \[[@r92]\]                                        

  TAT                   AME                             GRKKRRQRRRPPQGWC                                        liposome                                        Curcumin derivative             196                                •                              •                             \-                    \-                          \[[@r93]\]

  YGRKKRRQRRR           [SiO~2~@]{.ul}Fe~3~O~2~         Fe~3~O~2~                                               87                                              •                               •                                  \-                             \-                            \[[@r94]\]                                        

  TATre                 AME                             rrrqrrkkrGy                                             Nanoliposomes                                   OR2 (anti aβ\                   140                                •                              •                             •                     • ^l^                       \[[@r95]\]
                                                                                                                                                                aggregation\                                                                                                                                                                      
                                                                                                                                                                peptide)                                                                                                                                                                          

  TGN                   Unknown                         TGNYKALHPHNG                                            PEG-PCL                                         Docetaxel and AS1411 aptamer,   150-170                            •                              \-                            •                     •                           \[[@r96]\]

  TGNYKALHPHNG          PEG-PLGA NPs                    NAP (peptide)                                           151                                             \-                              \-                                 • ^g^                          • ^l^                         \[[@r97]\]                                        

  TGNYKALHPHNG          PEG-PLA                         QSH (anti ab\                                           96-111                                          •                               •                                  • ^g^                          \-                            \[[@r98]\]                                        
                                                        aggregation peptide)                                                                                                                                                                                                                                                                      

  THR                   TfR                             THRPPMWSPVWP                                            AuNP-LPFFD                                      LPFFD (anti ab\                 12                                 •                              •                             •                     \-                          \[[@r99]\]
                                                                                                                                                                aggregation peptide                                                                                                                                                               

  THRre                 TfR                             pwvpswmpprht                                            AuNP\                                           QDots                           10-15 (QDs),^h^ 12 nm (AuNP) ^h^   •                              •                             \-                    \-                          \[[@r63]\]
                                                                                                                QDots                                                                                                                                                                                                                             

  Peptide-22            LDLR                            c(&)MPRLRGC(&)                                          DSPE-PEG3400                                    c(RGDfK)+\                      100-125                            •                              •                             •                     •                           \[[@r100]\]
                                                                                                                                                                DOX                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Size as means of hydrodynamic diameter, measured by DLS; ^b^Endocytosis or transcytosis experiments in endothelial cell lines ^c^*In vivo* mice models otherwise noticed; ^d^Antiglioma effect otherwise noticed; ^e^inhibits Aβ aggregation ; ^f^AD model of *C. elegants*; ^g^ AD mice model; ^h^ & denotes cyclised peptides, nomenclature adapted from Spengler *et al.* (2005) \[[@r101]\]; ^i^size is determined by TEM; ^j^size is determined by SEM; ^k^Ischemia rat model; ^l^Cognitive test;
